http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 17 Oct 2025 12:46:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Verona+Pharma+plc++++++++++++++++++++++Filed+by%3A+BlackRock+Portfolio+Management+LLC/25470078.html si-local-file:///var/storage/secattach/20251017/25470078.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Verona+Pharma+plc++++++++++++++++++++++Filed+by%3A+BlackRock+Portfolio+Management+LLC/25470078.html Fri, 17 Oct 2025 12:46:00 -0400 O.01656413 VRNA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Verona+Pharma+plc++++++++++++++++++++++Filed+by%3A+BlackRock+Portfolio+Management+LLC/25470078.html si-local-file:///var/storage/secattach/20251017/25470078.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Verona+Pharma+plc++++++++++++++++++++++Filed+by%3A+BlackRock+Portfolio+Management+LLC/25470078.html Fri, 17 Oct 2025 12:46:00 -0400 O.01656413 VRNA http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Verona+Pharma+plc++++++++++++++++++++/25469823.html si-local-file:///var/storage/secattach/20251017/25469823.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Verona+Pharma+plc++++++++++++++++++++/25469823.html Fri, 17 Oct 2025 11:31:00 -0400 O.01656413 VRNA http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Verona+Pharma+plc++++++++++++++++++++/25469823.html si-local-file:///var/storage/secattach/20251017/25469823.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++Verona+Pharma+plc++++++++++++++++++++/25469823.html Fri, 17 Oct 2025 11:31:00 -0400 O.01656413 VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html <p>Soleno Therapeutics Inc. (NASDAQ: SLNO) appointed Mark W. Hahn as an independent director to its board of directors and as a member of its audit committee, according to a company statement. The addition brings the board to seven seats.</p> <p>Hahn brings nearly 30 years of chief financial officer experience in the biopharmaceutical sector. He previously served as CFO of Verona Pharma PLC from March 2020 until its acquisition by Merck & Co. Inc. for approximately $10 billion in October 2025. He also served as CFO of Dova Pharmaceuticals from January 2018 until its acquisition by Swedish Orphan Biovitrum for up to http://www.streetinsider.com/Board+Changes/Soleno+Therapeutics+adds+Mark+Hahn+to+board+of+directors/25447224.html Mon, 13 Oct 2025 08:00:49 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Press+Releases/Soleno+Therapeutics+Appoints+Biopharmaceutical+Executive+Mark+W.+Hahn+to+its+Board+of+Directors/25447204.html <p>REDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member of its Audit Committee. Mr. Hahn brings to Soleno’s Board nearly 30 years of CFO-level experience and has played a key role in numerous successful product launches, financings, and M&amp;A transactions within the life sciences sector. With the addition of Mr. Hahn, the Soleno Board increases to seven http://www.streetinsider.com/Press+Releases/Soleno+Therapeutics+Appoints+Biopharmaceutical+Executive+Mark+W.+Hahn+to+its+Board+of+Directors/25447204.html Mon, 13 Oct 2025 08:00:00 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Press+Releases/Soleno+Therapeutics+Appoints+Biopharmaceutical+Executive+Mark+W.+Hahn+to+its+Board+of+Directors/25447204.html <p>REDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member of its Audit Committee. Mr. Hahn brings to Soleno’s Board nearly 30 years of CFO-level experience and has played a key role in numerous successful product launches, financings, and M&amp;A transactions within the life sciences sector. With the addition of Mr. Hahn, the Soleno Board increases to seven http://www.streetinsider.com/Press+Releases/Soleno+Therapeutics+Appoints+Biopharmaceutical+Executive+Mark+W.+Hahn+to+its+Board+of+Directors/25447204.html Mon, 13 Oct 2025 08:00:00 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Press+Releases/Soleno+Therapeutics+Appoints+Biopharmaceutical+Executive+Mark+W.+Hahn+to+its+Board+of+Directors/25447204.html <p>REDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member of its Audit Committee. Mr. Hahn brings to Soleno’s Board nearly 30 years of CFO-level experience and has played a key role in numerous successful product launches, financings, and M&amp;A transactions within the life sciences sector. With the addition of Mr. Hahn, the Soleno Board increases to seven http://www.streetinsider.com/Press+Releases/Soleno+Therapeutics+Appoints+Biopharmaceutical+Executive+Mark+W.+Hahn+to+its+Board+of+Directors/25447204.html Mon, 13 Oct 2025 08:00:00 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA http://www.streetinsider.com/Press+Releases/Soleno+Therapeutics+Appoints+Biopharmaceutical+Executive+Mark+W.+Hahn+to+its+Board+of+Directors/25447204.html <p>REDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member of its Audit Committee. Mr. Hahn brings to Soleno’s Board nearly 30 years of CFO-level experience and has played a key role in numerous successful product launches, financings, and M&amp;A transactions within the life sciences sector. With the addition of Mr. Hahn, the Soleno Board increases to seven http://www.streetinsider.com/Press+Releases/Soleno+Therapeutics+Appoints+Biopharmaceutical+Executive+Mark+W.+Hahn+to+its+Board+of+Directors/25447204.html Mon, 13 Oct 2025 08:00:00 -0400 A.02472879 A.06822034 A.23874600 A.34535233 A.50114033 A.50201617 A.50205574 O.01380626 O.01656413 O.05375596 O.12846475 O.13601590 O.20026344 O.22806100 O.34165625 SLNO VRNA